Michele Fox
Concepts (268)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Mobilization | 11 | 2018 | 57 | 1.530 |
Why?
| Multiple Myeloma | 26 | 2024 | 2929 | 1.440 |
Why?
| Hematopoietic Stem Cell Transplantation | 13 | 2023 | 565 | 1.310 |
Why?
| Hematopoietic Stem Cells | 8 | 2018 | 184 | 1.290 |
Why?
| Blood Platelets | 5 | 2017 | 245 | 0.840 |
Why?
| Antigens, CD34 | 9 | 2018 | 66 | 0.780 |
Why?
| Melphalan | 4 | 2016 | 174 | 0.590 |
Why?
| Leukapheresis | 3 | 2018 | 14 | 0.580 |
Why?
| Bone Marrow Transplantation | 4 | 2016 | 116 | 0.560 |
Why?
| Blood Component Removal | 4 | 2018 | 10 | 0.560 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 2 | 2018 | 15 | 0.550 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 989 | 0.540 |
Why?
| Plasma Exchange | 3 | 2015 | 23 | 0.510 |
Why?
| Fetal Blood | 3 | 2023 | 68 | 0.470 |
Why?
| Cell Separation | 2 | 2013 | 89 | 0.420 |
Why?
| Pregnant Women | 1 | 2023 | 77 | 0.410 |
Why?
| Killer Cells, Natural | 2 | 2015 | 95 | 0.390 |
Why?
| Cell Proliferation | 5 | 2018 | 1007 | 0.370 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 156 | 0.360 |
Why?
| Transplantation, Autologous | 8 | 2013 | 466 | 0.360 |
Why?
| Myelodysplastic Syndromes | 2 | 2013 | 81 | 0.350 |
Why?
| Granulocyte Colony-Stimulating Factor | 4 | 2012 | 61 | 0.350 |
Why?
| Humans | 43 | 2024 | 49974 | 0.350 |
Why?
| Blood Specimen Collection | 1 | 2019 | 34 | 0.330 |
Why?
| Blood Transfusion | 2 | 2017 | 121 | 0.330 |
Why?
| Thalidomide | 4 | 2016 | 377 | 0.330 |
Why?
| Blood Volume | 1 | 2019 | 68 | 0.320 |
Why?
| Aged | 21 | 2017 | 9310 | 0.320 |
Why?
| Adult | 22 | 2019 | 13236 | 0.320 |
Why?
| Education, Distance | 1 | 2019 | 40 | 0.320 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 30 | 0.310 |
Why?
| Obstetrics | 1 | 2019 | 88 | 0.300 |
Why?
| Leukocytes, Mononuclear | 1 | 2018 | 116 | 0.300 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2017 | 39 | 0.300 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 5 | 0.290 |
Why?
| Blood Coagulation | 1 | 2017 | 56 | 0.290 |
Why?
| Middle Aged | 21 | 2018 | 12069 | 0.290 |
Why?
| Chromosome Aberrations | 3 | 2016 | 297 | 0.290 |
Why?
| Flow Cytometry | 2 | 2016 | 476 | 0.270 |
Why?
| Antibodies | 1 | 2016 | 154 | 0.270 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 121 | 0.270 |
Why?
| Aspirin | 1 | 2017 | 114 | 0.270 |
Why?
| Erythrocyte Transfusion | 2 | 2015 | 46 | 0.270 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 172 | 0.260 |
Why?
| Female | 22 | 2023 | 26472 | 0.250 |
Why?
| Hemoglobins, Abnormal | 1 | 2015 | 4 | 0.250 |
Why?
| Heparin | 1 | 2015 | 92 | 0.250 |
Why?
| Thrombocytopenia | 1 | 2015 | 85 | 0.250 |
Why?
| Stem Cell Transplantation | 2 | 2013 | 181 | 0.240 |
Why?
| Factor VIII | 1 | 2014 | 23 | 0.240 |
Why?
| Leukocytes | 2 | 2011 | 66 | 0.240 |
Why?
| ADAM Proteins | 1 | 2014 | 20 | 0.240 |
Why?
| Anemia, Sickle Cell | 1 | 2015 | 96 | 0.230 |
Why?
| Male | 21 | 2019 | 25241 | 0.230 |
Why?
| Follow-Up Studies | 8 | 2024 | 2182 | 0.220 |
Why?
| Internship and Residency | 1 | 2019 | 443 | 0.220 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 34 | 0.220 |
Why?
| Leukemia | 1 | 2013 | 65 | 0.210 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.210 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 614 | 0.210 |
Why?
| Graft Survival | 4 | 2011 | 150 | 0.210 |
Why?
| Prognosis | 6 | 2018 | 1942 | 0.200 |
Why?
| Aldehyde Dehydrogenase | 1 | 2011 | 26 | 0.200 |
Why?
| Transplantation Conditioning | 3 | 2003 | 83 | 0.200 |
Why?
| Boronic Acids | 2 | 2013 | 182 | 0.190 |
Why?
| Pyrazines | 2 | 2013 | 187 | 0.190 |
Why?
| Plateletpheresis | 1 | 2010 | 7 | 0.190 |
Why?
| Blood Preservation | 1 | 2010 | 26 | 0.190 |
Why?
| Retrospective Studies | 8 | 2018 | 6108 | 0.180 |
Why?
| Transplantation, Homologous | 5 | 2016 | 139 | 0.180 |
Why?
| Cryopreservation | 1 | 2010 | 31 | 0.180 |
Why?
| Blood Proteins | 1 | 2010 | 82 | 0.180 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.180 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2007 | 93 | 0.170 |
Why?
| Cell Survival | 5 | 2011 | 600 | 0.170 |
Why?
| Graft vs Host Disease | 5 | 2003 | 75 | 0.170 |
Why?
| Receptors, KIR | 1 | 2008 | 13 | 0.160 |
Why?
| HIV Infections | 1 | 2013 | 357 | 0.160 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 828 | 0.160 |
Why?
| Myeloablative Agonists | 1 | 2007 | 30 | 0.150 |
Why?
| Cell Movement | 2 | 2006 | 247 | 0.150 |
Why?
| Immunosuppressive Agents | 2 | 2014 | 221 | 0.150 |
Why?
| Treatment Outcome | 11 | 2013 | 5141 | 0.150 |
Why?
| Dexamethasone | 3 | 2024 | 430 | 0.140 |
Why?
| Risk Factors | 7 | 2015 | 3613 | 0.140 |
Why?
| Models, Genetic | 1 | 2006 | 170 | 0.140 |
Why?
| Osteogenesis | 2 | 2006 | 352 | 0.130 |
Why?
| Young Adult | 4 | 2019 | 3958 | 0.130 |
Why?
| Models, Statistical | 1 | 2007 | 224 | 0.130 |
Why?
| Combined Modality Therapy | 4 | 2014 | 637 | 0.130 |
Why?
| Macrophages | 1 | 2018 | 363 | 0.130 |
Why?
| Gene Expression Profiling | 2 | 2007 | 1032 | 0.130 |
Why?
| Platelet Count | 3 | 2017 | 72 | 0.130 |
Why?
| Cytokines | 2 | 2006 | 612 | 0.130 |
Why?
| Incidence | 3 | 2017 | 1003 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 244 | 0.120 |
Why?
| Antineoplastic Agents | 3 | 2012 | 1171 | 0.120 |
Why?
| Time Factors | 1 | 2010 | 2903 | 0.120 |
Why?
| Pregnancy | 2 | 2023 | 2607 | 0.110 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 2016 | 28 | 0.110 |
Why?
| Disease-Free Survival | 3 | 2016 | 454 | 0.110 |
Why?
| Blood Banks | 1 | 2023 | 18 | 0.110 |
Why?
| Bone Marrow Cells | 1 | 2004 | 191 | 0.110 |
Why?
| Metaphase | 2 | 2016 | 44 | 0.110 |
Why?
| Bone Diseases | 1 | 2004 | 99 | 0.110 |
Why?
| Osteoblasts | 1 | 2006 | 450 | 0.110 |
Why?
| Cell Count | 3 | 2011 | 147 | 0.110 |
Why?
| Cyclosporine | 1 | 2003 | 64 | 0.110 |
Why?
| Tacrolimus | 1 | 2003 | 52 | 0.100 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 5 | 0.100 |
Why?
| ABO Blood-Group System | 1 | 2002 | 15 | 0.100 |
Why?
| Universities | 1 | 2023 | 161 | 0.100 |
Why?
| Kaplan-Meier Estimate | 3 | 2007 | 466 | 0.100 |
Why?
| Coculture Techniques | 3 | 2018 | 146 | 0.100 |
Why?
| T-Lymphocyte Subsets | 1 | 2001 | 39 | 0.090 |
Why?
| Osteoclasts | 1 | 2004 | 425 | 0.090 |
Why?
| Models, Biological | 1 | 2004 | 727 | 0.090 |
Why?
| Heart Failure | 1 | 2006 | 458 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 65 | 0.090 |
Why?
| Prospective Studies | 4 | 2016 | 2364 | 0.090 |
Why?
| Lung Diseases | 1 | 2001 | 92 | 0.090 |
Why?
| Thrombosis | 1 | 2003 | 248 | 0.090 |
Why?
| Cancer Vaccines | 1 | 2010 | 78 | 0.090 |
Why?
| Dendritic Cells | 1 | 2010 | 133 | 0.080 |
Why?
| Erythroid Precursor Cells | 1 | 2019 | 15 | 0.080 |
Why?
| Birth Weight | 1 | 2019 | 120 | 0.080 |
Why?
| Hematocrit | 1 | 2018 | 44 | 0.080 |
Why?
| Medical Waste | 1 | 2017 | 2 | 0.080 |
Why?
| Cell Aggregation | 1 | 2017 | 6 | 0.080 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2008 | 74 | 0.080 |
Why?
| Lymphoma | 1 | 2018 | 66 | 0.070 |
Why?
| Arkansas | 2 | 2017 | 1977 | 0.070 |
Why?
| Program Evaluation | 1 | 2019 | 354 | 0.070 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 27 | 0.070 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 44 | 0.070 |
Why?
| Logistic Models | 2 | 2017 | 888 | 0.070 |
Why?
| Lung | 1 | 2001 | 486 | 0.070 |
Why?
| Adolescent | 3 | 2015 | 6356 | 0.070 |
Why?
| Neoplasms | 1 | 2007 | 1235 | 0.070 |
Why?
| Risk | 1 | 2017 | 320 | 0.070 |
Why?
| Fibrosis | 1 | 2017 | 179 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1376 | 0.070 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 105 | 0.070 |
Why?
| Recurrence | 2 | 2008 | 652 | 0.070 |
Why?
| Curriculum | 1 | 2019 | 401 | 0.070 |
Why?
| Hemorrhage | 1 | 2017 | 197 | 0.070 |
Why?
| Hemoglobin J | 1 | 2015 | 3 | 0.060 |
Why?
| Hemoglobin, Sickle | 1 | 2015 | 6 | 0.060 |
Why?
| Hemoglobin C | 1 | 2015 | 6 | 0.060 |
Why?
| Blood Donors | 1 | 2015 | 31 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1037 | 0.060 |
Why?
| Neoplasm Proteins | 1 | 2016 | 322 | 0.060 |
Why?
| Age Factors | 3 | 2005 | 1087 | 0.060 |
Why?
| Autoantibodies | 1 | 2014 | 116 | 0.060 |
Why?
| Reproducibility of Results | 1 | 2017 | 1193 | 0.060 |
Why?
| Blotting, Western | 1 | 2015 | 601 | 0.060 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 32 | 0.050 |
Why?
| Viral Load | 1 | 2013 | 76 | 0.050 |
Why?
| Transplantation Chimera | 3 | 2003 | 15 | 0.050 |
Why?
| Acute Disease | 1 | 2013 | 366 | 0.050 |
Why?
| Benzylamines | 1 | 2012 | 15 | 0.050 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 28 | 0.050 |
Why?
| Heterocyclic Compounds | 1 | 2012 | 28 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2015 | 973 | 0.050 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 56 | 0.050 |
Why?
| Infant, Newborn | 1 | 2019 | 2772 | 0.050 |
Why?
| Clinical Protocols | 1 | 2012 | 108 | 0.050 |
Why?
| Immune Tolerance | 1 | 2011 | 96 | 0.050 |
Why?
| Dimethyl Sulfoxide | 1 | 2010 | 12 | 0.050 |
Why?
| Isotonic Solutions | 1 | 2010 | 18 | 0.050 |
Why?
| Platelet Transfusion | 1 | 2010 | 28 | 0.050 |
Why?
| P-Selectin | 1 | 2010 | 32 | 0.050 |
Why?
| Algorithms | 2 | 2005 | 615 | 0.050 |
Why?
| Sodium Chloride | 1 | 2010 | 57 | 0.050 |
Why?
| Platelet Aggregation | 1 | 2010 | 71 | 0.050 |
Why?
| Platelet Activation | 1 | 2010 | 46 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2007 | 577 | 0.040 |
Why?
| Feasibility Studies | 1 | 2011 | 375 | 0.040 |
Why?
| Hypersensitivity | 1 | 2010 | 77 | 0.040 |
Why?
| Haplotypes | 1 | 2008 | 83 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 66 | 0.040 |
Why?
| Ligands | 1 | 2008 | 204 | 0.040 |
Why?
| Arginase | 1 | 2018 | 35 | 0.040 |
Why?
| Hemoglobins | 1 | 2008 | 107 | 0.040 |
Why?
| Polyethylene Glycols | 1 | 2008 | 93 | 0.040 |
Why?
| Age Distribution | 1 | 2007 | 168 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2007 | 82 | 0.040 |
Why?
| Tissue Donors | 2 | 2003 | 111 | 0.040 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 47 | 0.040 |
Why?
| Recombinant Proteins | 1 | 2008 | 486 | 0.040 |
Why?
| Multigene Family | 1 | 2006 | 56 | 0.040 |
Why?
| Mice | 2 | 2018 | 5739 | 0.030 |
Why?
| Chromosome Deletion | 1 | 2007 | 140 | 0.030 |
Why?
| Chromosome Mapping | 1 | 2006 | 156 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2007 | 259 | 0.030 |
Why?
| Angiogenesis Inhibitors | 1 | 2007 | 187 | 0.030 |
Why?
| Cell Line | 1 | 2008 | 1000 | 0.030 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 185 | 0.030 |
Why?
| Interleukin-10 | 1 | 2006 | 84 | 0.030 |
Why?
| Cell Communication | 1 | 2006 | 69 | 0.030 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 114 | 0.030 |
Why?
| Stroke Volume | 1 | 2006 | 116 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2006 | 91 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2007 | 903 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2006 | 120 | 0.030 |
Why?
| Databases, Factual | 1 | 2007 | 658 | 0.030 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 30 | 0.030 |
Why?
| Bromodeoxyuridine | 1 | 2004 | 19 | 0.030 |
Why?
| Annexin A5 | 1 | 2004 | 13 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2006 | 555 | 0.030 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 48 | 0.030 |
Why?
| Phagocytosis | 1 | 2004 | 48 | 0.030 |
Why?
| Survival Rate | 1 | 2006 | 894 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2006 | 388 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2006 | 3129 | 0.030 |
Why?
| Cell Division | 1 | 2004 | 292 | 0.030 |
Why?
| Chronic Disease | 1 | 2006 | 567 | 0.030 |
Why?
| Plasmapheresis | 1 | 2003 | 11 | 0.030 |
Why?
| RANK Ligand | 1 | 2004 | 179 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 240 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2006 | 945 | 0.030 |
Why?
| Interleukin-6 | 1 | 2004 | 264 | 0.030 |
Why?
| Salvage Therapy | 2 | 2003 | 139 | 0.030 |
Why?
| Cohort Studies | 1 | 2006 | 1422 | 0.030 |
Why?
| Child | 1 | 2015 | 6847 | 0.030 |
Why?
| NF-kappa B | 1 | 2004 | 314 | 0.030 |
Why?
| Carrier Proteins | 1 | 2004 | 304 | 0.030 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.030 |
Why?
| Animals | 2 | 2018 | 13187 | 0.020 |
Why?
| Antigens, CD | 1 | 2003 | 219 | 0.020 |
Why?
| Survival Analysis | 2 | 2003 | 653 | 0.020 |
Why?
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 2 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2001 | 21 | 0.020 |
Why?
| Cell Differentiation | 1 | 2004 | 651 | 0.020 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2001 | 39 | 0.020 |
Why?
| Clone Cells | 1 | 2001 | 74 | 0.020 |
Why?
| Graft Rejection | 1 | 2002 | 161 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 14 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2006 | 1455 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 43 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 51 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 69 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2001 | 116 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1537 | 0.020 |
Why?
| Interferon-gamma | 1 | 2010 | 177 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 595 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2001 | 369 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2010 | 170 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2001 | 164 | 0.020 |
Why?
| Vaccination | 1 | 2010 | 266 | 0.020 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 156 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| Probability | 1 | 2003 | 164 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 70 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 2003 | 206 | 0.010 |
Why?
| Cyclophosphamide | 1 | 2003 | 165 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2003 | 376 | 0.010 |
Why?
| Remission Induction | 1 | 2003 | 207 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 426 | 0.010 |
Why?
| Neutrophils | 1 | 2003 | 145 | 0.010 |
Why?
| Doxorubicin | 1 | 2003 | 233 | 0.010 |
Why?
| Cisplatin | 1 | 2003 | 278 | 0.010 |
Why?
| Drug Resistance, Neoplasm | 1 | 2003 | 308 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2003 | 740 | 0.010 |
Why?
| Disease Progression | 1 | 2003 | 825 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|